Search Results - "Endres, Mariah"

Phase II trial of split-dose R-CHOP for older patients with diffuse large B-cell lymphoma (DLBCL) by Shah, Nirav Niranjan, Szabo, Aniko, Rajguru, Saurabh, Devata, Sumana, Howard, Mitch, Pereira, Deepa, Endres, Mariah, Longo, Walter L., Hamadani, Mehdi, Fenske, Timothy S., Fletcher, Christopher David

“…7554 Background: Management of elderly DLBCL is limited by age associated comorbid conditions and decreased tolerance of chemotherapy regimens. Many elderly or…”
Get full text

Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma by Chang, Julie E, Wang, Tuo, Kim, KyungMann, Folstad, Matthew, Endres, Mariah, Howard, Mitch, Kenkre, Vaishalee, Fletcher, Christopher, Rajguru, Saurabh

“…Lenalidomide (LEN) and rituximab (RTX) have independently improved progression-free survival (PFS) in CLL, leading to interest in use of LEN + RTX (R2)…”
Get full text

Minimal Residual Disease (MRD) Testing By Next Generation Sequencing (NGS) after Two Cycles (CY) of Non-Intensive Chemoimmunotherapy Is Predictive of Remission Duration and Need for Maintenance Therapy (MT) in Previously Untreated Mantle Cell Lymphoma (MCL): A Wisconsin Oncology Network Study by McQuinn, Danielle, Hyun, Meredith, Kim, KyungMann, Kenkre, Vaishalee P, Fletcher, Christopher D, Rajguru, Saurabh A, Pophali, Priyanka A, Endres, Mariah, Howard, Mitch, Wassenaar, Tim, Warren, Ruth Callaway, Mattison, Ryan J, Wisinski, Kari B, Chang, Julie E

“…Introduction: Despite the variable course of MCL, limited prospective markers exist to identify more indolent disease. MCL is often diagnosed in older patients…”
Get full text

Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study by Chang, Julie E., McQuinn, Danielle, Hyun, Meredith, Kim, KyungMann, Kenkre, Vaishalee P., Rajguru, Saurabh A., Pophali, Priyanka A., Endres, Mariah, Howard, Mitch, Wassenaar, Tim, Warren, Ruth Callaway, Mattison, Ryan J., Wisinski, Kari B., Fletcher, Christopher D.

“…Obinutuzumab is hypothesized to improve progression-free survival (PFS) combined with bendamustine induction in mantle cell lymphoma (MCL). Measurable-residual…”
Get full text